Press

Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

Feb 3 • 3 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP”) portfolio. The Company has received a Notice of Allowance from the United States Patent and Trademark Office (the “USPTO”) for United States (“U.S.”) patent application no….

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

Feb 3 • 4 min read

PharmaTher Holdings Ltd. (OTCQB: PHRRF | CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2…

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Feb 3 • 4 min read

Psyence Group Inc. (CSE: PSYG. | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has entered into a partnership with Eden Labs LLC, a product development and extraction technology company that has developed intellectual property and methodologies around the extraction…

Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial

Feb 3 • 3 min read

Apex Labs Ltd, a pharmaceutical company optimizing the standard of mental health care with psilocybin, is pleased to announce its approval by Health Canada to begin APEX-002-A01-03, the world’s largest take home psilocybin clinical trial approved to date. This randomized, double-blind, placebo-controlled phase 2b study will evaluate the efficacy, safety and tolerability of APEX-52 microdose, orally administered…

PSYC Provides Shareholders with Key Corporate Updates and Highlights Objectives for 2023

Feb 1 • 12 min read

PSYC Corporation (OTC Pink Market: PSYC), parent company to Spotlight Media Corporation, a multimedia leader positioned at the intersection where all things psychedelics and cannabis converge, is pleased to provide its shareholders with an overview of recent key corporate updates along with insight into some of the prime objectives the Company is outlining for the year ahead. Sacha…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435